Current Pathogenesis and Treatment of Cutaneous Lupus Erythematosus

Cut Putri Hazlianda; Ika Diamanda

doi:10.47353/jsocmed.v2i12.107

Current Pathogenesis and Treatment of Cutaneous Lupus Erythematosus

Cut Putri Hazlianda
Department of Dermatology Venereology and Aestethic, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Ika Diamanda
Department of Dermatology Venereology and Aestethic, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Abstract

Lupus erythematosus (LE) is a chronic autoimmune illness with a broad range of clinical symptoms. These conditions can range from systemic lupus erythematosus (SLE), which affects different organ systems in the body, to cutaneous lupus erythematosus (CLE), which affects only the skin. The precise pathophysiology of CLE is unknown, although it appears to include a complicated interaction of genetic predisposition and environmental stimuli such as UV light, medications, trauma, and hormones. The emergence of the inflammatory infiltrate seen in CLE lesions has also been documented in several studies; this information is crucial for figuring out which specific inflammatory mediators are responsible for tissue damage. Currently prescribed medications for CLE often include antimalarials, systemic corticosteroids, immunosuppressants, and immunomodulators; cytotoxic drugs are only used in the most severe instances.

Similar Articles

Al-Ma’ Arij Akbar Lubis, Cut Aryfa Andra, Andre Pasha Ketaren, Relationship between QTc interval prolongation and mortality of acute ischaemic stroke patients during treatment and three months after treatment at Adam Malik Hospital , Journal of Society Medicine: Vol. 3 No. 3 (2024): March
Roni Abimanyu, Andika Sitepu, Ali Nafiah Nasution, Comparison of Syntax II Score And Grace Score As Predictors of Major Cardiovascular Events 30 Days after Treatment in STEMI Undergoing PPCI , Journal of Society Medicine: Vol. 3 No. 6 (2024): June
Edlin, Mual Kristian Sinaga, Prolotherapy in Chronic Coccydynia , Journal of Society Medicine: Vol. 2 No. 2 (2023): February
Raka Jati Prasetya, Nurita Dian Kestriani Saragi Sitio, The Efficacy of High Flow Nasal Cannula (HFNC) in Chronic Obstructive Pulmonary Disease (COPD): a Case Report , Journal of Society Medicine: Vol. 2 No. 6 (2023): June
Cut Putri Hazlianda, Dina Arwina Dalimunthe, Awalia Astarina, Generalized Exfoliative Dermatitis Suspected Caused by COVID-19 Vaccine : A Case Report , Journal of Society Medicine: Vol. 2 No. 12 (2023): December
Adhika Syaputra, Dadik Wahyu Wijaya, Achsanuddin Hanafie, Patterns of Antibiotic Use in The One Hour Bundle Treatment of Sepsis , Journal of Society Medicine: Vol. 1 No. 3 (2022): December
Cindy Giovanni, Nurita Dian Kestriani Saragi Sitio, Role of Intravenous Immunoglobulin (IVIG) in Patients with Guillain Barre Syndrome with Severe Community Pneumonia in The Intensive Care Unit (ICU) , Journal of Society Medicine: Vol. 3 No. 3 (2024): March
Yudhisman Imran, Ainaya Az Zahra, The Use of NIHSS as an Assessment of Acute Stroke Severity , Journal of Society Medicine: Vol. 3 No. 2 (2024): February
Tasrif Hamdi, Transversus Abdominis Plane (TAP) Steroid Block for Chronic Abdominal Pain Caused by Chronic Postoperative Pain , Journal of Society Medicine: Vol. 2 No. 1 (2023): January
Army Zaka Anwary, Indriasari, Role of CRRT (Continuous Renal Replacement Therapy) as Management of Cardiac Arrest Patient with Postpartum Acute Lung Edema and Cardiomyopathy in the ICU , Journal of Society Medicine: Vol. 2 No. 6 (2023): June

1 2 3 4 > >>

You may also start an advanced similarity search for this article.

PDF

Published at

31. December 2023
https://doi.org/10.47353/jsocmed.v2i12.107
Issue:

Vol. 2 No. 12 (2023): December
Section:

Articles
Keywords:

Lupus erythematosus Cutaneous lupus erythematosus Pathogenesis Treatment
References:

Guo LN, Nambudiri VE. Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis. Clin Rheumatol. 2021;40(2):491–9.

Rees F, Doherty M, Grainge M, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology 2017b;56(11):1945–61.

Little AJ, Vesely MD. Cutaneous lupus erythematosus: Current and future pathogenesis-directed therapies. Yale J Biol Med. 2020;93(1):81–95.

Chang AY, Ghazi E, Okawa J, Werth VP. Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol 2013;149(1):104–6.

Billi AC, Gharaee-Kermani M, Fullmer J, Tsoi LC, Hill BD, Gruszka D, et al. The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity. JCI Insight. 2019;4(8).

Scofield RH, Bruner GR, Namjou B, Kimberly RP, RamseyGoldman R, Petri M, et al. Klinefelter’s syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58:2511–7

Cooney CM, Bruner GR, Aberle T, Namjou-Khales B, Myers LK, Feo L, et al. 46,X,del(X)(q13) Turner’s syndrome women with systemic lupus erythematosus in a pedigree multiplex for SLE. Genes Immun. 2009;10:478–81

Wang J, Syrett CM, Kramer MC, Basu A, Atchison ML, Anguera MC. Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X. Proc Natl Acad Sci U S A. 2016;113:E2029–38.

Syrett CM, Paneru B, Sandoval-Heglund D, et al. Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases. JCI Insight. 2019;4

Souyris M, Cenac C, Azar P, et al. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3:Eaap8855.

E.S Robinson, V.P. Werth. The Role of Cytokines in the Pathogenesis of Cutaneous Lupus Erythematosus. Elsevier. 2015; p 1-7

Jiaxuan C, Shuzhen L, Wanxian P, Fengbiao G, et al,. Life Factors Acting on Systemic Lupus Erythematosus. Frontiers in Immunology. 2022:1-10.

Blaine C, Kailey M, Shreya T, Esther M. Alcohol as a friend or foe in autoimmune diseases: a role for gut mictobiome. Taylor & Francis Group. 2021; 13(1): 1-15.

Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–32.

Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K. Fitzpatrick’s Dermatology in General Medicine. Ninth. New York: McGraw Hill; 2019.

Marco Q, Guido M, Marco DA, Cinzia B, Vincenzo C. Viral Infections and Systemic Lupus Erythematosus: New Players in a Old Story. MDPI. 2021; 13: 1-29

Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–32.

Günther C. Nucleic acid immunity in the pathogenesis of cutaneous lupus erythematosus. Front Immunol. 2019;10(JULY):1–9.

Kathryn C, Eric FM. Systemic Lupus Erythematosus: A Clinical Update. Internal Medicine Journal. 2021;51:1219-1228

Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–32.

Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: Current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208–14.

Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1–8.

Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019 Feb 18;129(3):1359–71.

Zimmermann N, Wolf C, Schwenke R, Lüth A, Schmidt F, Engel K, et al. Assessment of Clinical Response to Janus Kinase Inhibition in Patients with Familial Chilblain Lupus and TREX1 Mutation. JAMA Dermatology. 2019;155(3):342–6.

Fornaro M, Coladonato L, Venerito V, Cacciapaglia F, Lopalco G, Iannone F. Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. Rheumatol (United Kingdom). 2020;59(5):1188.

You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: The experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–3.

Van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, et al. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, PlaceboControlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020;72(5):761–8.

Lu Q, Long H, Chow S, Hidayat S, Danarti R, Listiawan Y, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. 2021;123(8):102707.
Share:

Z

Hazlianda, C. P., & Diamanda, I. (2023). Current Pathogenesis and Treatment of Cutaneous Lupus Erythematosus. Journal of Society Medicine, 2(12), 392–402. https://doi.org/10.47353/jsocmed.v2i12.107